Breast cancer preventive therapy ignored

Five in six women who are at increased risk of breast cancer reject therapy that reduces their chances of developing the disease, UK researchers say.

Their meta-analysis of 26 international studies including more than 21,000 women at increased risk of developing breast cancer shows just 16.3% chose to take selective estrogen reuptake modulators (SERMs) such as raloxifene and tamoxifen to mitigate their risk.